Herantis Pharma Plc · OMXHEX:HRTIS

Herantis Pharma — Vator Unicorn Summit, Stockholm 2019

20 slides from Herantis Pharma's conference presentation, Nov 27, 2019

  1. Slide 1: Toward clinical breakthroughs based on leading science

    Toward clinical breakthroughs based on leading science Vator Unicorn Summit, Stockholm 27 Nov 2019 Pekka Simula, CEO 1 11/25/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  2. Slide 2: Disclaimer

    Disclaimer • This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc (‘Company’). The information provided in this presentation shall not be considered sufficient for making any investment decisions related to the Company. Anyone considering an investment in

  3. Slide 3: Breaking the boundaries of standard therapeutic approaches

    Breaking the boundaries of standard therapeutic approaches 3 11/25/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  4. Slide 4: Herantis' target indications

    Herantis’ target indications Parkinson’s disease (PD) Secondary lymphedema PD is an incurable brain disease whose first symptoms include tremors, muscle stiffness → Symptoms grow worse with disease progression → Known drugs only treat motor symptoms, only for a while Lymphedema (LE) is chronic, prog

  5. Slide 5: Parkinson's facts and Lymphedema facts

    Parkinson’s facts: Lymphedema facts: • Second most common • 140 million LE patients neurodegenerative disease: • 2 million breast cancer 7-10 million patients diagnosis annually • Estimated annual financial burden of PD is $50 billion → 30% of patients who undergo mastectomy will develop • Progressi

  6. Slide 6: By developing disease-modifying treatments, we fight both human suffering and societal costs

    By developing disease-modifying treatments, we fight both human suffering and societal costs 11/25/19 6 11/25/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  7. Slide 7: Parkinson's is treated with levodopa… since 1960's!

    Parkinson’s is treated with levodopa… since 1960’s! • Professor Arvid Carlsson → Lund University: Role of dopamine in the brain (Science 1958) → First preclinical studies with levodopa → Nobel price 2000 on signal transduction in the nervous system 7 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc.

  8. Slide 8: PD: Our drug candidate CDNF promotes neuronal survival and recovery

    PD: Our drug candidate CDNF promotes neuronal survival and recovery through multiple relevant mechanisms 8 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  9. Slide 9: CDNF doubled the number of neurons in a PD model

    CDNF doubled the number of neurons in a PD model* Vehicle 150 µg CDNF 80% loss of dopaminergic neurons Doubled the number of dopaminergic neurons • Disease model: MPTP lesion model in aged Rhesus monkey • Three monthly CDNF doses doubled the number of DA neurons • Significant improvement in gross mo

  10. Slide 10: CDNF may change how patients live with PD

    CDNF may change how patients live with PD Currently in Phase 1-2 clinical study funded by EU: “Leading science, greatest potential to advance clinical practice” Ø Study fully recruited: 17 patients randomized in CDNF vs. placebo groups Ø Topline results expected in Q1/2020 Ø First-in-human study in

  11. Slide 11: Next generation: xCDNF

    Next generation: xCDNF • Common challenge in brain diseases is drug delivery in the brains à CDNF is dosed directly in brains using medical device • Next step: we have shown that certain CDNF fragments: 1. Retain its biological activity (comparable efficacy in PD models) 2. Penetrate the BBB à much

  12. Slide 12: Lymfactin gene therapy for curing secondary lymphedema

    Lymfactin® gene therapy for curing secondary lymphedema 12 11/25/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  13. Slide 13: Lymfactin: VEGF-C gene therapy to reconstitute the lymphatic system

    Lymfactin®: VEGF-C gene therapy to reconstitute the lymphatic system 1. A single Lymfactin® injection results in local VEGF-C expression for about 2 weeks 2. VEGF-C is the natural human protein that promotes the growth of lymphatic capillaries 3. Lymphatic capillaries mature into functional lymphati

  14. Slide 14: Lymfactin development

    Lymfactin® development • Actively recruiting patients with breast cancer associated LE (BCAL) → Adjunct to lymph node transplantation surgery, which attempts to relieve symptoms → Study centers: 5 university hospitals in Sweden and Finland • Safety established in Phase 1 study with same approach → P

  15. Slide 15: Lymphedema: Market and awareness

    Lymphedema: Market and awareness • 140 million LE patients worldwide • €600M market for Lymfactin® as an adjunct therapy in BCAL* → Significant potential in other lymphedemas • Lymphedema awareness increases → Herantis is a partner of LE&RN, international patient advocacy group → Hollywood superstar

  16. Slide 16: Summary and Public Offering in Sweden

    Summary and Public Offering in Sweden 11/25/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  17. Slide 17: CDNF and Lymfactin are in placebo-controlled studies targeting unmet clinical needs

    Based on leading science, CDNF and Lymfactin® are in placebo-controlled studies targeting unmet clinical needs COMPANY’S ESTIMATE ON MARKET POTENTIAL EUR 600m EUR 1.6bn Not provided 17 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  18. Slide 18: Selected financials as reported 1H/2019

    Selected financials as reported 1H/2019 H1/2019 H1/2018 Cash end of period 5.6 MEUR 4.0 MEUR Cash flow from operations -2.7 MEUR -1.8 MEUR Personnel 9 9 • Market cap approximately 450 MSEK (Nov 18th, 2019) • Last funding round in 3/2019 → Cornerstone investor: Swedbank Robur’s healthcare fund Medica

  19. Slide 19: Public company in Finland since 2014: Now dual-listing in Sweden

    Public company in Finland since 2014: HRTIS Now dual-listing in Sweden First North listed • Herantis announced on 11 Nov 2019: →Public offering in Sweden and Denmark, and private placement: max 618,018 shares to be issued at 71 SEK (~€6.65) per share →Target: Herantis’ shares listed in Nasdaq First

  20. Slide 20: Thank you

    Thank you E-mail: pekka.simula@herantis.com Twitter: @HerantisPharma Blog: http://herantis.com/blog/ 20 11/25/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

Herantis Pharma — Vator Unicorn Summit, Stockholm 2019 on 6ix